Effect of combined bevacizumab and temozolomide treatment on intramedullary spinal cord tumor

So Jung Gwak, Sung Su An, Moon Sul Yang, Eunhae Joe, Donghyun Kim, Do Heum Yoon, Keung Nyun Kim, Yoon Ha

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Study Design. C6 glioma cells and an intramedullary spinal cord tumor model were used to evaluate the effect of bevacizumab (Avastin) or temozolomide (TMZ). Objective. In this study, we hypothesized that treatment with bevacizumab accelerates the therapeutic effect of TMZ on intramedullary gliomas in an animal model. Summary of Background Data. Recently therapies for the management of intramedullary malignant gliomas include surgery, chemotherapy, and radiotherapy. Concurrent or adjuvant TMZ has been considered an emerging new treatment for intramedullary malignant gliomas; however, high-dose application of TMZ has limitation of side effect. Methods. C6 glioma cells were injected into the T5 level of the spinal cord, and TMZ and bevacizumab were administered 5 days after C6 inoculation (n = 7 for each group). Tumor size was analyzed using histology and magnetic resonance imaging at 13 days after tumor inoculation. Results. Histological analyses and magnetic resonance imaging findings showed that combined treatment with TMZ and bevacizumab reduced tumor mass. The tumor volume of control group was 2.8-fold higher than combined therapy (P < 0.05). Neurological outcomes demonstrated that combined therapy improved hind limb function more than TMZ-Alone group or control group (P < 0.05). Conclusion. This study shows that bevacizumab could be useful in combination with TMZ to increase the therapeutic benefits of TMZ for intramedullary spinal cord tumors.

Original languageEnglish
JournalSpine
Volume39
Issue number2
DOIs
Publication statusPublished - 2014 Jan 15

Fingerprint

temozolomide
Spinal Cord Neoplasms
Glioma
Therapeutics
Magnetic Resonance Imaging
Bevacizumab
Neoplasms
Control Groups
Therapeutic Uses
Tumor Burden

All Science Journal Classification (ASJC) codes

  • Orthopedics and Sports Medicine
  • Clinical Neurology

Cite this

Gwak, So Jung ; An, Sung Su ; Yang, Moon Sul ; Joe, Eunhae ; Kim, Donghyun ; Yoon, Do Heum ; Kim, Keung Nyun ; Ha, Yoon. / Effect of combined bevacizumab and temozolomide treatment on intramedullary spinal cord tumor. In: Spine. 2014 ; Vol. 39, No. 2.
@article{30d86bb1e22041d595c80a9c4704286d,
title = "Effect of combined bevacizumab and temozolomide treatment on intramedullary spinal cord tumor",
abstract = "Study Design. C6 glioma cells and an intramedullary spinal cord tumor model were used to evaluate the effect of bevacizumab (Avastin) or temozolomide (TMZ). Objective. In this study, we hypothesized that treatment with bevacizumab accelerates the therapeutic effect of TMZ on intramedullary gliomas in an animal model. Summary of Background Data. Recently therapies for the management of intramedullary malignant gliomas include surgery, chemotherapy, and radiotherapy. Concurrent or adjuvant TMZ has been considered an emerging new treatment for intramedullary malignant gliomas; however, high-dose application of TMZ has limitation of side effect. Methods. C6 glioma cells were injected into the T5 level of the spinal cord, and TMZ and bevacizumab were administered 5 days after C6 inoculation (n = 7 for each group). Tumor size was analyzed using histology and magnetic resonance imaging at 13 days after tumor inoculation. Results. Histological analyses and magnetic resonance imaging findings showed that combined treatment with TMZ and bevacizumab reduced tumor mass. The tumor volume of control group was 2.8-fold higher than combined therapy (P < 0.05). Neurological outcomes demonstrated that combined therapy improved hind limb function more than TMZ-Alone group or control group (P < 0.05). Conclusion. This study shows that bevacizumab could be useful in combination with TMZ to increase the therapeutic benefits of TMZ for intramedullary spinal cord tumors.",
author = "Gwak, {So Jung} and An, {Sung Su} and Yang, {Moon Sul} and Eunhae Joe and Donghyun Kim and Yoon, {Do Heum} and Kim, {Keung Nyun} and Yoon Ha",
year = "2014",
month = "1",
day = "15",
doi = "10.1097/BRS.0000000000000070",
language = "English",
volume = "39",
journal = "Spine",
issn = "0362-2436",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

Effect of combined bevacizumab and temozolomide treatment on intramedullary spinal cord tumor. / Gwak, So Jung; An, Sung Su; Yang, Moon Sul; Joe, Eunhae; Kim, Donghyun; Yoon, Do Heum; Kim, Keung Nyun; Ha, Yoon.

In: Spine, Vol. 39, No. 2, 15.01.2014.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effect of combined bevacizumab and temozolomide treatment on intramedullary spinal cord tumor

AU - Gwak, So Jung

AU - An, Sung Su

AU - Yang, Moon Sul

AU - Joe, Eunhae

AU - Kim, Donghyun

AU - Yoon, Do Heum

AU - Kim, Keung Nyun

AU - Ha, Yoon

PY - 2014/1/15

Y1 - 2014/1/15

N2 - Study Design. C6 glioma cells and an intramedullary spinal cord tumor model were used to evaluate the effect of bevacizumab (Avastin) or temozolomide (TMZ). Objective. In this study, we hypothesized that treatment with bevacizumab accelerates the therapeutic effect of TMZ on intramedullary gliomas in an animal model. Summary of Background Data. Recently therapies for the management of intramedullary malignant gliomas include surgery, chemotherapy, and radiotherapy. Concurrent or adjuvant TMZ has been considered an emerging new treatment for intramedullary malignant gliomas; however, high-dose application of TMZ has limitation of side effect. Methods. C6 glioma cells were injected into the T5 level of the spinal cord, and TMZ and bevacizumab were administered 5 days after C6 inoculation (n = 7 for each group). Tumor size was analyzed using histology and magnetic resonance imaging at 13 days after tumor inoculation. Results. Histological analyses and magnetic resonance imaging findings showed that combined treatment with TMZ and bevacizumab reduced tumor mass. The tumor volume of control group was 2.8-fold higher than combined therapy (P < 0.05). Neurological outcomes demonstrated that combined therapy improved hind limb function more than TMZ-Alone group or control group (P < 0.05). Conclusion. This study shows that bevacizumab could be useful in combination with TMZ to increase the therapeutic benefits of TMZ for intramedullary spinal cord tumors.

AB - Study Design. C6 glioma cells and an intramedullary spinal cord tumor model were used to evaluate the effect of bevacizumab (Avastin) or temozolomide (TMZ). Objective. In this study, we hypothesized that treatment with bevacizumab accelerates the therapeutic effect of TMZ on intramedullary gliomas in an animal model. Summary of Background Data. Recently therapies for the management of intramedullary malignant gliomas include surgery, chemotherapy, and radiotherapy. Concurrent or adjuvant TMZ has been considered an emerging new treatment for intramedullary malignant gliomas; however, high-dose application of TMZ has limitation of side effect. Methods. C6 glioma cells were injected into the T5 level of the spinal cord, and TMZ and bevacizumab were administered 5 days after C6 inoculation (n = 7 for each group). Tumor size was analyzed using histology and magnetic resonance imaging at 13 days after tumor inoculation. Results. Histological analyses and magnetic resonance imaging findings showed that combined treatment with TMZ and bevacizumab reduced tumor mass. The tumor volume of control group was 2.8-fold higher than combined therapy (P < 0.05). Neurological outcomes demonstrated that combined therapy improved hind limb function more than TMZ-Alone group or control group (P < 0.05). Conclusion. This study shows that bevacizumab could be useful in combination with TMZ to increase the therapeutic benefits of TMZ for intramedullary spinal cord tumors.

UR - http://www.scopus.com/inward/record.url?scp=84895075022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895075022&partnerID=8YFLogxK

U2 - 10.1097/BRS.0000000000000070

DO - 10.1097/BRS.0000000000000070

M3 - Article

VL - 39

JO - Spine

JF - Spine

SN - 0362-2436

IS - 2

ER -